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Abstract 
Palliation and repair of increasingly complex congenital heart defects as well as the 
emergence of novel contexts has led to multiple scenarios in which a real or potential 
risk of thromboembolism may exist. While various anticoagulation methodologies 
have been well defined for adults, there are few studies relating directly to pediatric 
patients. This article reviews a number of specific pediatric disease states, the 
representative pediatric literature, and, where appropriate, the corresponding adult 
literature. In so doing, the art and science of pediatric cardiac anticoagulation is 
defined with the hope to engender further thought regarding future directions of study 
and therapy. 
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Introduction 
As medical and surgical care for patients with congenital heart disease progresses, 
an increasing number of immediate and long-term complications have been 
recognized. One important complication is the development of thrombus arising 
within the chambers, on the valves, or in the walls of the heart, or on implanted 
devices and prosthetic material placed in the heart or its downstream arteries or 
upstream veins. These clots can cause local complications, such as their mass effect 
obstructing flow through chambers or vessels, or impairing valve function. They can 
also lead to embolic events, such as coronary artery obstruction with myocardial 
infarction, cerebrovascular accident, or mesenteric artery obstruction. (Figure 1)  
 
 
Figure 1 Large pedunculated thrombus in the left atrium as well as thrombus across 
the foramen ovale and into the right atrium, presumably from placement of an 
umbilical venous catheter across the foramen ovale. The left-sided portion of the 
thrombus subsequently embolized to the descending aorta, resulting in the patient's 
demise. 
 
 
 
 
Much of what is known regarding cardiac thrombotic phenomena derives from adult 
studies. In fact, many of the recommendations that pediatric cardiologists use are 
either empirically derived and then passed on by tradition or based on adult data, 
with little or no supporting evidence from pediatric studies. Some of these prevention 
and treatment plans are probably reasonable, as there is fairly good correlation 
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between certain adult and pediatric pathophysiologic states. Furthermore, a number 
of these studies may never be done, as the patient population is small and the risk-
benefit ratio is unclear. Yet, various pathophysiologic and anatomic states are 
germane to pediatric and adolescent patients. Specifically those patients with 
complex congenital heart defects (e.g. the Glenn and Fontan physiology and the 
Blalock-Taussig shunt) that have undergone palliative operations, which place them 
at high risk for thromboembolism. These require long-term study. Further 
complicating matters are the changes in the normal levels of prothrombotic and 
antithrombotic proteins with age. This article will review the topic of anticoagulation in 
various pediatric cardiac intervention and disease states where both art and science 
simultaneously operate. The aim here is to provide the practitioner with general 
guidelines as well as define areas in which several legitimate methods exist. 
Anticoagulation of prosthetic valves will not be discussed here, as this can be 
considered a fundamentally unique indication with its own extensive body of literature 
in which there is overall consensus on the approach to anticoagulation without 
significant distinctions drawn between pediatric and adult patients. 
 Principles and agents of anticoagulation 
Advances in pediatric cardiac intervention have demanded broader expertise in 
applying principles of anticoagulation to a new and diverse set of indications. Initially, 
much of the understanding and principles of use for coagulation inhibiting agents that 
are used in children was derived from adult data; in fact, this still continues for newer 
medications. Only recently has a greater understanding of the age-related 
differences in the hemostasis pathway led both to more effective use of these agents 
as well as furthering pediatric trials to better define the guidelines for use, monitoring 
efficacy, and management of complications.1,2 The use of anticoagulation agents in 
other, non-cardiac disease states, such as in thromboembolism and cancer, has 
benefited therapeutic regimen design for cardiac-specific uses, as well. The result is 
a growing knowledge base upon which further studies lead to frequent updates in 
guidelines for use.1 
The most frequently used anticoagulation agents are unfractionated heparin and 
warfarin (other warfarin-like derivatives include phenprocoumon, which has a much 
longer half-life, and acenocoumarol, which has a shorter half-life and increased 
bleeding complications). Typically, heparin is used for either short-term 
anticoagulation use, due to its relatively short half-life, or for initiation of long-term 
anticoagulation therapy in preparation for conversion to warfarin. Heparin is a 
mucopolysaccharide that functions as a catalyst in the activation of antithrombin III. 
Antithrombin III activation causes subsequent inactivation of thrombin, plasmin, and 
factors IX, X, XI, and XII, resulting in impaired coagulation. Typical anticoagulation 
regimens include a loading dose of 75 to 100 units/kg followed by a maintenance 
dose of 28 units/kg/hour for children under age 1 year and 20 units/kg/hour for 
children over age 1 (based on decreased normal infant antithrombin levels).1 The 
dose in older children, 18 units/kg/hour, is similar to that in adults. Doses of 50 
units/kg given as a bolus, which have been employed in studies and are widely 
accepted, were found to be inadequate in establishing appropriate initial 
anticoagulation.3 Monitoring of therapeutic efficacy has centered on the use of the 
activated partial thromboplastin time, although this method has been difficult to 
standardize. Other monitoring methods include achieving heparin concentrations at a 
level of 0.2 to 0.4 units/ml by titration with protamine, or anti-factor Xa levels of 0.35 
to 0.70 units/ml. However, this has been deemed to be accurate only approximately 
70% of the time in children.3 Therefore, when converting to an oral anticoagulant 
agent either immediately or after prolonged heparin therapy, it is recommended that 
two separate therapeutic measurements of the international normalized ratio (INR) 
be obtained before stopping heparin.4 Alternatively, for brief use, such as during 
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arterial access in the cardiac catheterization laboratory, monitoring with the activated 
clotting time (ACT) to obtain levels of approximately 200 seconds (double the normal 
time) can be performed quickly and accurately.5 
Low-molecular weight heparin (LMWH) is gaining popularity as a safer and more 
efficacious alternative than unfractionated heparin for several reasons. Its half-life is 
longer than that of unfractionated heparin. It can be given subcutaneously without the 
need for intravenous access. It has a stable, reproducible anticoagulant effect. It has 
a lower incidence of heparin-associated side effects, including thrombocytopenia and 
osteoporosis. Dosing of enoxaparin or reviparin depends on whether the patient is 
younger or older than 2 months of age. For enoxaparin, the initial dose for children 
less than 2 months is 1.5 mg/kg subcutaneously; children over 2 months receive 1.0 
mg/kg every 12 hours. For reviparin, initial dosing for children greater than 2 months 
is 100 units/kg subcutaneously every 12 hours; children less than 2 months old 
require 150 units/kg every 12 hours. To achieve maintenance, anti-factor Xa levels 
are followed with adjustment to keep levels from 0.5 to 1.0 units/ml. 
Warfarin, acenocoumarol, and phenprocoumon are all similar oral anticoagulant 
medications that block the formation in the liver of the vitamin K-dependent clotting 
factors II, VII, IX, and X. There are age-related adjustments for the use of these 
agents, as infant vitamin K-dependent clotting factors are 50% of adult levels, and 
childhood amounts are 80% of adult levels through adolescence. Due to the 
significantly shorter half-life of acenocoumarol and the longer half-life of 
phenprocoumon, the medical literature suggests that warfarin is the agent of 
choice.6,7 Typical loading doses for children are 0.2 mg/kg; these are then followed 
by dose adjustments based on the international normalized ratio (INR) values of 
prothrombin times. These dose adjustments relate to the original loading dose, and 
are dependent upon the target INR range. INR is usually kept between 2.0 and 3.0 
for treatment of thromboembolism, and between 2.5 and 3.5 for prophylaxis of 
thrombosis in patients with congenital heart valves. However, so-called “low-dose 
therapy,” which keeps the INR between 1.4 and 1.9, has also been studied in 
children who either have a new thrombus in the setting of a history of recurrent 
thrombus, or have an older thrombus. Higher dose therapy to keep the INR between 
3.0 and 4.5 has been suggested to be efficacious specifically for patients who have 
recurrent thromboembolism despite appropriate INR measurements between 2.0 and 
3.0, or for patients with certain hypercoagulable states, such as protein S or protein C 
deficiency.8 
Aspirin functions specifically as a platelet-inhibiting agent, causing its effects by 
irreversibly binding to cyclooxygenase. This prevents the eventual formation of 
thromboxane A2, thus decreasing platelet aggregation. This effect lasts until new 
platelets with unbound cyclooxygenase are produced and released, which requires 
seven to ten days after aspirin therapy has ceased. Typical doses that have been 
used range from 1 to 10 mg/kg/day, although there is little actual data supporting 
specific pediatric doses of aspirin for platelet inhibition. Most commonly, doses of 3 to 
5 mg/kg/day are quoted as “platelet-inhibiting” or “antiplatelet therapy.”9 
Dipyridamole, another antiplatelet agent, inhibits phosphodiesterase and increases 
cyclic adenosine monophosphate, thus decreasing platelet aggregation. Dosing is 
typically 2 to 5 mg/kg/day, although there is also limited documentation on 
appropriate dosing and uses in pediatric patients. Most literature supports its use as 
adjunctive therapy in mechanical prosthetic cardiac valves.10,11 
Pentoxifylline, a methylxanthine-derived agent, acts in a novel way by enhancing 
erythrocyte flexibility and decreasing blood viscosity. It also inhibits platelet 
aggregation, inhibits tumor necrosis factor alpha, and causes vasodilation. It is not 
considered, however, a true anticoagulant. Although approved for the treatment of 
peripheral vascular disease in adults, it has had some initial investigation in pediatric 
cardiac disease. Doses of 20 mg/kg/day were used in a pilot study to achieve modest 
improvement of pulmonary blood flow in patients with inoperable cyanotic heart 
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disease and polycythemia.12 It has also been used in conjunction with IVIG and ASA 
in the therapy of Kawasaki's disease, with a dose of 20 mg/kg/day leading to a 
debatable decrease in the formation of coronary artery aneurysms.13 
There are a number of newer anticoagulation agents, such as platelet inhibition 
agents (ticlopidine and clopidogrel), which have been gaining popularity, and the 
glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, and tirofiban), in which there is 
limited pediatric data. Use and dosing of these drugs will be discussed later in 
specific sections. Further detailed information regarding all of the anticoagulation and 
antiplatelet agents mentioned here can be found in both updated reviews on pediatric 
antithrombosis1 as well as in a recent text assessing pediatric thrombosis.14 What 
follows is a discussion of anticoagulation as it relates to various pediatric cardiac 
disease conditions. 
 Dysrhythmias and anticoagulation 
Patients with congenital heart disease that have had extensive atrial surgery are at 
greater risk for later development of dysrhythmias, both in the immediate post-
operative period15 and during long-term follow-up.16 With increased sensitivity of 
transesophageal echocardiographic surveillance, more of these thrombi are now 
detectable and must be addressed prior to initiation of cardioversion (either electrical 
or chemical). However, there are no studies specifically involving pediatric patients in 
which prior anticoagulation of a patient is performed and assessed for relative risk of 
embolism post-cardioversion versus a patient who has not been anticoagulated. 
Therefore, specific risk factors are not well described, and prediction of which 
patients will be at greater risk for embolic events is not possible. There has been 
speculation, however, that patients in whom spontaneous echocardiographic contrast 
can be seen, or those with poor ventricular function, are at increased risk for 
thrombus development.16 
Pediatric patients with atrial arrhythmias often will be cardioverted without the use of 
prior anticoagulation if there is no evidence of intra-atrial thrombus by transthoracic 
echocardiography, in some cases, or by transesophageal echocardiography. Much of 
the practice for anticoagulation of pediatric patients in chronic atrial arrhythmias 
derives from the adult literature, although there is individual variation. Using atrial 
fibrillation as an example, typical adult patients under age 60, with or without heart 
failure, no structural disease, and no other systemic risk factors can be 
prophylactically managed with either no anticoagulation or just aspirin 325 mg per 
day.17 With increased age, coronary artery or valvular disease, systemic diseases, or 
heart failure, warfarin anticoagulation is initiated, with maintenance of an INR of 2.0-
3.0. During elective DC or chemical cardioversion, patients who have had their atrial 
dysrhythmia for at least 48 hours (or for unknown duration) are given warfarin to 
maintain an INR of 2 to 3 for three to four weeks prior to as well as after 
cardioversion. For those patients requiring immediate cardioversion, the 
recommendation is for urgent heparinization to increase aPTT to 1.5-2.0 times 
normal prior to cardioversion, followed by oral anticoagulation maintenance as 
described. 
 Glenn/Fontan anastomoses 
Glenn and Patino first described their vena caval-pulmonary artery shunt over 45 
years ago,18 and Fontan and Baudet's original article describing the physiologic 
surgical repair for tricuspid atresia is now over 30 years old.19 In that time, numerous 
modifications to these initial procedures have evolved. However, the basic physiology 
remains, in that there is direct flow from the vena cavae into the pulmonary arteries 
without an intervening ventricle and, typically now, without an interposed valve. The 
lack of these two entities means that there is no active pumping of blood into the 
pulmonary tree, and no way to prevent retrograde flow or pressure transmission. 
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Moreover, unlike the description of the original anastomoses, which divided superior 
and inferior vena caval return between the branch pulmonary arteries, current 
reconstructive operations maintain continuity between both pulmonary arteries and 
both vena cavae. This allows any obstruction or downstream pressure load to be 
transmitted through the entire system. It also allows two oppositely directed flows to 
dissipate their kinetic energy as they meet. The sequelae of this have led to the 
modifications mentioned above, so that the majority of the repairs that are 
undertaken now are no longer the direct right-atrium-to-pulmonary-artery connection, 
but are more of the lateral tunnel (total cavopulmonary connection) or the external 
conduit connection. 
The other major modification that has been made to the Fontan physiology is that of 
the creation of a fenestration to allow decompression of the right-sided system by 
right-to-left shunting. Used by a number of centers, this fenestration can be left as is 
or later occluded by transcatheter device or by surgical closure. Despite these 
various modifications, a prominent, and not uncommon, adverse finding in these 
patients is the development of thrombi and embolic events, with a prevalence of 
anywhere from 5-33%.20–23 (Figure 2) Of note, the actual incidence of these may be 
even higher, as several studies show that the sensitivity of transthoracic 
echocardiography to detect thrombi is less than that of transesophageal 
echocardiography, even in smaller children,22,24–27 and nearly all of the numerous 
studies reporting the presence of thrombi were retrospective in nature. Therefore 
most studies likely underestimate these incidences. An exception is the study from 
the German Heart Center, in Munich, which performed a partially prospective study 
of 52 patients. This study demonstrated that transesophageal echo was more 
sensitive than transthoracic echo, and identified thrombus formation in 1/3 of their 
patients.22 
 
Figure 2 Older Fontan repair, with a direct atriopulmonary anastomosis, 
demonstrating spontaneous echocardiographic contrast and a mural thrombus 
attached anteriorly to the atrial wall. 
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The etiology of thrombus formation is unclear. Multiple derangements of liver-
generated proteins has been noted, most prominently that of a relative deficiency of 
protein C.20,21,28–33 However, decreased antithrombin III, protein S, prothrombin times, 
plasminogen, factors II, VII, IX, X, and XIII levels, elevated thrombin-antithrombin III 
complex, plasmin-antiplasmin complex, D-dimer, prothrombin, activated partial 
thromboplastin times, factor VIII, gamma glutamyltranspeptidase (GGTP), alanine 
aminotransferase, aspartate aminotransferase, bilirubin, and alkaline phosphatase 
levels have also been variously reported.20,21,28–33 Note that prothrombin times have 
been listed as both decreased and increased, depending on the reporting study. 
Although it has been correctly noted that there are age-related maturational levels of 
these hemostatic factors and that some of the earlier data did not take this into 
account,2,14,34,35 much of the later data still demonstrate overall lower absolute 
measurements and subnormal levels of protein C as well as other decreased 
anticoagulant factors for age as compared to normal.30–33 
The changes in hemostatic factors associated with the Fontan surgery may directly 
result in protein-losing enteropathy seen in these patients. A small study from 
Denver, looking at hepatic function in these patients, demonstrated an increased 
galactose elimination half-life in the entire study group in addition to abnormal GGTP, 
prothrombin, and factor V levels in over 70% of their study group. Of note, liver 
biopsies in four of eleven patients demonstrated cirrhosis or varying degrees of 
fibrosis.36 Hsia and colleagues at Great Ormond Street assessed Doppler flow and/or 
catheter measurements across the portal vein, hepatic vein, and inferior vena cava of 
Fontan and control patients, found clues that may lend insight into the pathogenesis 
of liver damage.37,38 They found that gravity and exhalation adversely affected 
various aspects of flow both in the older atriopulmonary connection Fontan patients 
as well as in those with the newer total cavopulmonary connections when compared 
to normals. Between alterations in pulsatility, flow direction, and pressures, they 
demonstrated central venous, hepatic venous, and portal hypertension in their 
Fontan patients with a decreased transhepatic gradient, suggesting global 
congestion of capacitance sinusoids. They suggest that the constant pressure, which 
was shown to be further increased in certain venous systems in patients with worse 
NYHA status or protein-losing enteropathy, overwhelms autoregulatory responses 
and further deranges local flow as well as affecting regional drainage patterns. This 
may lead to the later GI complications, such as ascites and protein-losing 
enteropathy. It may also lead to the direct hepatic damage. (Figure 3). 
Other putative associated risk factors for thrombosis that have emerged include: 
bilateral discordant sized superior vena cavae employed in the creation of a 
cavopulmonary anastomoses, postoperative low mean arterial saturations,39 atrial 
dysrhythmias,23,39 large fenestrations (> 4 mm),41 and protein-losing enteropathy 
through direct loss of clotting regulatory proteins.20 These associated factors have 
been suggested, but given the relatively small numbers of patients their presence 
may be circumstantial and not causal. 
As is so common in many of these pediatric cardiac disease entities, long-term 
double-blind, randomized, placebo controlled studies of anticoagulation efficacy and 
outcome do not exist. Several empiric methods for dealing with this increasingly 
recognized complication exist. Andrew's Canadian study group suggests initial 
perioperative anticoagulation followed by no anticoagulation, by warfarin, or by 
aspirin for six months.1 Some centers do not anticoagulate at all, unless patients 
have dysrhythmias or prosthetic valves.42 There are centers that give warfarin for 
three months followed by life-long aspirin.43 Some treat with warfarin for six months 
followed by no anticoagulation or by ASA.44 One center in Rome, however, continues 
their oral anticoagulation for at least one year and then initiates ASA.45 Others use 
aspirin six months post-operatively.46 Finally, there are those who give warfarin or 
aspirin life-long. Of those who treat with warfarin indefinitely, many treat for an INR of 
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2.5 to 3.0 while others attempt to achieve and maintain an INR of 3.0-4.5.47 However, 
there is reported use of a combination of ASA 10 mg/kg/day plus warfarin to maintain 
an INR of 1.5.41 By and large, the centers reporting their anticoagulation were not 
performing comparisons of various regimens, and were reporting retrospectively. Of 
note, thrombus formation has been demonstrated while patients were on “low-dose” 
aspirin, warfarin, dicoumarol, or heparin.23,48 At the present time, there is a 
multicenter prospective study in Canada and Australia that is addressing these 
issues whose results are pending. 
 
Figure 3 Angiographic and echocardiographic demonstration of complete occlusion 
of the Fontan anastomosis by thrombosis, with development of collateral circulation 
bringing lower extremity flow to the branch pulmonary arteries. The Glenn 
anastomosis is patent. 
 
 
Interventional catheterization 
 Balloon angioplasty 
Interventional cardiac catheterization has expanded significantly since its inception to 
include: balloon valvuloplasty, balloon angioplasty, angioplasty plus placement of one 
or multiple stents in both arterial and venous vessels, placement of occlusion devices 
in the ductus arteriosus, atrial septum, and other abnormal arterial or venous 
connections, transseptal puncture, endomyocardial biopsy, and radiofrequency 
ablation. Due to concern for thrombus formation at sites of intimal rupture or at 
prosthetic device placement as well as concern for neointimal proliferation, 
anticoagulation has been used in several specific situations. In one study from the 
Royal Brompton Hospital, patients with pulmonary atresia and stenotic 
aortopulmonary collateral vessels underwent balloon angioplasty and stent 
placement to improve pulmonary flow.49 Patients were heparinized in the 
catheterization laboratory, then had their heparin continued until they were orally 
anticoagulated to an INR of 2.5-3.0. This was maintained for 3 or 6 months in a total 
of 11 patients. One patient, who was noncompliant with anticoagulation therapy, had 
restenosis at the distal end of the stent after systemic saturations were noted to be 
significantly lower by three months post-intervention. It was unclear whether this 
stenosis was due to thrombus or neointimal hyperplasia, although it was surmised to 
be due to the former, as the other patients who underwent later catheterization 
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(median 11-month follow-up) demonstrated no evidence of neointimal hyperplasia. 
Their institutional recommendation is to anticoagulate with warfarin for 6 months 
post-intervention, despite having had no patients develop any complications when 
treated with 3 months of warfarin. Two multicenter studies have used a combination 
of aspirin and dipyridamole empirically for stent placement in larger pulmonary 
arteries post-surgery.50,51 The Royal Brompton study, however, mentions that their 
choice of anticoagulation is due to their patients having a higher hemoglobin plus 
smaller, tortuous vessels with low or non-pulsatile flow. 
Much of the research in this area is driven not by pediatric “large vessel” intervention 
therapies but by adult coronary arterial intervention, with attempts to devise models 
of atherosclerosis as well as mechanisms of inhibition of re-occlusion of coronary 
arteries after balloon angioplasty with or without stenting. Therefore, the use of post-
interventional anticoagulation regimens appears to be anecdotal at best. For 
example, research with heparin administration by either continuous infusion or by 
release by perivascular polymer matrices have demonstrated not only inhibition of 
post-interventional thrombus formation but also decreased neointimal proliferation 
after stenting of rabbit arterial vessels.52,53 Further direction may come from the adult 
studies, as newer modalities such as brachytherapy (the use of intracoronary 
radiation),54 sirolimus (and other drug)-eluting stents,55 and combination antiplatelet 
therapies have been used in attempting to decrease thrombosis and the need for 
either reintervention or revascularization. These may be interesting models of 
therapy to consider when choosing a short- or long-term anticoagulation treatment 
post-stenting. Two studies have demonstrated that aspirin plus ticlopidine after 
stenting reduced the occurrence of cardiac death, myocardial infarction (MI), 
coronary bypass surgery, or repeat angioplasty over aspirin plus IV heparin plus 
phenprocoumon,56 or reduced the combined incidence of death, MI, or repeat 
revascularization, plus bleeding complications.57 A third study, the STARS trial, 
demonstrated that the composite endpoint of death, revascularization, thrombosis, or 
MI was least in patients treated with aspirin plus ticlopidine as compared to aspirin 
alone or aspirin plus warfarin.58 
Clopidogrel has also been shown in randomized trials to be as effective as ticlopidine 
after stenting.59,60 Ticlopidine has been used rarely in pediatric patients, although it 
has been used in the treatment of coronary thrombosis in Kawasaki's disease61 and 
several other vascular entities, such as Kasabach-Merritt syndrome62 and even in 
adolescent with primary pulmonary hypertension.63 Dosing has been 5-8 mg/kg BID 
in combination with low-dose aspirin; peak response is up to 14 days of treatment 
(though it can be seen in 2 to 5 days after loading dose), and has been associated 
with GI disturbance, rash, neutropenia, agranulocytosis, and thrombotic 
thrombocytopenic purpura in adults.62,64 There are no specific studies or reports that 
utilize clopidogrel in the treatment of children. Peak response is in 3 to 7 days of 
initiation of treatment; diarrhea, rash, and pruritus have been seen, although the 
amount of GI hemorrhage is reportedly less than that associated with ticlopidine.64,65 
The study of glycoprotein IIb/IIIa inhibitors (GP IIb/IIIa) has opened up the use of a 
new set of adjunctive therapeutic sites that, when inhibited, decreases aggregation of 
platelets by antagonizing the binding of fibrinogen and other adhesion proteins with 
platelets. Their use, as with the other drugs above, has been studied primarily in the 
setting of coronary angioplasty. They have been demonstrated to decrease the 
occurrence of ischemic complications post-intervention. However, there have been 
inconsistent results with these agents, as well as an overall lack of efficacy in the 
orally administered inhibitors.66 Abciximab, a chimeric human-mouse monocolonal 
antibody FAb fragment, was used along with ticlopidine in elective coronary artery 
angioplasty with stenting, and was found to decrease the endpoints of death, MI, or 
revascularization at 30 days as compared to angioplasty without stenting or 
angioplasty plus placebo.67 It has been used in the pediatric treatment of Kawasaki's 
disease in the setting of large coronary artery aneurysms containing thrombi, with 
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resolution of aneurysms and clots without development of ischemia,68 and is 
suggested to enhance vascular remodeling as well as speeding aneurysm 
resolution.69 Abciximab is administered as a bolus dose of 0.25 mg/kg 10 to 60 
minutes prior to intervention, then given continuously 0.125 mcg/kg/min for up to 12 
hours, with bleeding as its main complication.68,70 Eptifibatide and tirofiban have not 
been reported as being used in children in the literature. The concomitant use of 
these agents with heparin have allowed for the reduction in overall heparin dosing in 
coronary angioplasty,71 although the need for the higher activated clotting times seen 
in adult coronary intervention appears to be not as relevant in pediatric balloon 
interventional catheterization. 
An interesting new development is the use of activated protein C polymer coating on 
stents. Animal trials in a rabbit iliofemoral artery injury model have shown that the 
stents with polymerized activated protein C had no evidence of occlusion as 
compared to uncoated stents or those coated with bovine serum albumin.72 
Since coronary arteries are relatively smaller vessels, it is difficult to compare 
outcomes and methods in these small vessels with those of larger vessels. Recent 
data from Texas Children's Hospital suggest that neointimal growth and restenosis 
are uncommon for as much as 10 years after initial placement of Palmaz stents.73 
Moderate (1 to 1.5 mm) or severe (>1.5 mm) neointimal proliferation occurred in 
1.8%, and restenosis occurred in 2% of their patients. Restenosis was felt to occur 
due to several risk factors: lack of overlap of tandem stents, sharp angulation of the 
stent within the vessel, stent overdilation, and stent placement in abnormal tissue 
substrate (e.g. patients with Williams syndrome). They felt that the risk of neointimal 
proliferation increased with overdilation of the stent when it was initially placed, which 
has been previously suggested in the setting of coronary artery stenting.74 Another 
recent study of stenting in pulmonary arteries of patients with pulmonary atresia/VSD 
from San Francisco, distal pulmonary arteries that were approximately the size of 
coronary arteries showed a greater rate of restenosis and even occlusion within the 
stent, although their overall numbers were smaller.75 Other studies using Wallstents 
demonstrated intimal proliferation at a rate of 28%, using growth >30% of the vessel 
diameter as their definition.76 Although they did not define their specific 
anticoagulation regimens, they did report that there was no difference in neointimal 
proliferation between patients treated with aspirin and those treated with warfarin. 
And, as another potential confounding factor, they referenced a study in which 
Wallstents were found to be more thrombogenic than Palmaz stents in intrahepatic 
portosystemic shunts.77 
So, what of using the stenting of larger arteries, such as adult iliofemoral arteries, as 
a better model? Again, a number of studies exist that use different regimens, different 
stents, and have different outcomes. An Australian group used 5000 units of heparin 
during the placement of Strecker or Wall stents in femoral or popliteal arteries, then 
aspirin 150 mg/day on discharge; their results demonstrated acute thrombosis (within 
48 hours) in 6.3%, late occlusion in an additional 12.9% from 2 to 18 months, and 
stenosis in 22.5% of their patients from 4 to 15 months post-placement.78 Another 
group, who stented iliofemoral veins with Wall, Palmaz, and Gianturco stents, used 
intraprocedural heparin of 5000 units, then maintained systemic heparinization post-
stenting for three days to keep aPTT 75 to 100 seconds.79 They then overlapped 
warfarin therapy for 3-6 months. Their study showed no significant thromboembolic 
phenomena, but had occlusion in 32% and stenoses in 22% of their stented vessels. 
An interesting case report, in which an adult with heparin-induced thrombocytopenia 
and thrombosis syndrome was anticoagulated with argatroban during carotid artery 
stenting, had a successful outcome (with no recurrence of neurologic symptoms at 
six-month follow-up).80 Their regimen consisted of an initial argatroban bolus of 350 
µg/kg followed by continuous infusion of 25 µg/kg/min, which was later decreased to 
15 µg/kg/min when the initial ACT was greater than 700 seconds. After conclusion of 
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the procedure, the patient was treated with ticlopidine 250 mg twice a day for 6 
weeks and aspirin (no dose given) indefinitely. 
In choosing an established adult model for anticoagulation in balloon angioplasty with 
stenting, it must be realized that there are multiple confounding factors. Certainly, 
one of the most important confounders is the size and type of vessel. Stenotic or 
hypoplastic pulmonary arteries with little atherosclerotic load or damage but possibly 
very abnormal growth characteristics may respond, heal, interact with the clotting 
system, and endothelialize very differently from a formerly fully patent iliac or 
coronary artery with local plaque formation as well as damage from concurrent 
tobacco use or infection. As well, the stent size, the use of overdilation, the 
underlying characteristics of the vessel (such as cystic medial necrosis), and residual 
compliance of the vessels all impact on long-term outcomes. At this point, the use of 
a randomized, placebo-controlled study of various anticoagulation regimens for stent 
placement may be difficult, in that the accepted practice is the use of some form of 
antiplatelet therapy at a minimum for some period of finite or unlimited time. 
 Occlusion devices 
Anticoagulation strategies for the placement of steel coils and larger devices to 
occlude the ductus or septal defects have developed along divergent pathways. 
Except for the routine heparinization associated with the arterial catheterization, 
anticoagulation after placement of Gianturco steel coils in the ductus arteriosus or 
other vessel with the intention of occlusion is not desirable. The coils have Dacron 
fibers arrayed from them, which act specifically as a procoagulant backbone for 
platelets and other clotting factors to quickly create a thrombus. So, after a 
combination of mass effect causing gross occlusion plus successful thrombosis, the 
coil becomes endothelialized. The Rashkind occlusion device, although larger, 
seems to have had the same anticoagulation strategy.81 
Atrial septal occlusion devices, which have been described now for over 25 years,82 
have taken a different tack toward anticoagulation. The large array of devices that 
are now available or that are in clinical trials create large profile thrombogenic 
surfaces in the atria, which are also sites of low velocity flow. Yet, fibrin-platelet 
deposition is the initial backbone onto which the eventual complete endothelialization 
of the device occurs, which has been demonstrated in multiple devices.83–88 
Transesophageal echocardiographic evaluation of adults three days after placement 
of the ASDOS device have demonstrated layers of echodense material on the both 
surfaces, which remained constant or decreased over time with follow-up.89 Mobile 
and pedunculated thrombi were also seen in at least 25% of the patients that were 
followed clinically and with echocardiography until resolution. There were no adverse 
embolic events noted, and neither the presence nor absence of atrial enlargement, 
residual shunting, or sinus rhythm had any effect on the formation or resolution of 
these clots, which stabilized in the vast majority by six months. Despite this need for 
rapid thrombosis, though, the presence of thrombosis in this location confers a higher 
risk in the non-anticoagulated patient, and may add risk to even those patients who 
are platelet inhibited.90 Patients with coagulation disorders can also develop gross 
thrombus with embolic phenomena;91 in this specific case report, as in others 
mentioned in previously mentioned clinical circumstances, the thrombus was missed 
by transthoracic echocardiography, and was only diagnosed by transesophageal 
study. This patient, who suffered from factor XII deficiency, had been anticoagulated 
with heparin and had started phenprocoumon at the time of an acute cerebrovascular 
accident. 
Residual shunts also are felt to be risk factors for formation of thrombi, especially in 
the setting of occluding a foramen ovale for presumed recurrent paradoxical 
embolism.92 This study assessed five different devices, and found that aspirin dosed 
at 100 mg/day for three to six months after placement did not appear to increase or 
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decrease risk of recurrent embolism. But, even a warfarinized INR of 3.5 in a woman 
six weeks after placement of a device for an atrial septal defect did not prevent a 
subsequent embolic event; she was found not to have any disorders of thrombosis.93 
Therefore, though anticoagulation appears to be necessary for placement of septal 
defect occlusion devices, and may need to be continued longer pending complete 
closure of residual defects with the history of paradoxical embolism, it may still be 
incomplete to prevent thrombosis. 
There is a number of varying anticoagulation methods that seems to be based more 
on institutional practice than the actual device used. All groups used heparinization 
during the actual procedures, then diverged from there. A multicenter study in 
Germany using the Das Angel Wings device recommended the use of aspirin at a 
dose of 2-3 mg/kg/day over six months.94 Sievert, at his institution in Frankfurt, 
Germany, employed warfarin or aspirin for two to six months post-procedure with the 
ASDOS device in adults.84 Later, as the head of a multi-institutional German study, 
he divided anticoagulation into a pediatric regimen, using aspirin for six months and 
an adult regimen, using warfarin for six months.95 Hausdorf's group at Berlin, also 
using the ASDOS, used heparin 600 u/kg/d IV the first day, 400 u/kg/d the second 
day, and 200 u/kg the third day to keep the antithrombin III greater than 90%, then 
gave aspirin 2 to 3 mg/kg/day for six months post-procedure.96 The multicenter 
international study groups placing the Sideris buttoned device used aspirin 5 to 10 
mg/kg/day in children and 325 mg/day in adults for a total of three months.97–99 The 
German CardioSEAL trials in Hannover used 2-3 mg/kg/d of aspirin daily for six 
months post-occlusion.100 When Hausdorf evaluated its replacement, the self-
centering STARflex, patients in this multi-center trial were also treated with the same 
heparin, then aspirin, regimen that he used while at Berlin using the ASDOS.101 
There have been several side-by-side device comparison studies, as well. 
A British study comparing the Amplatzer and the buttoned devices in children used a 
flat dose of aspirin 75 mg/day in all their children (some up to 91 kg) for 3 to 6 
months.102 Two more comparative studies in adults used, presumably, platelet-
inhibiting doses of aspirin in their adults for 3 to 6 months.103,104 Few of these studies 
demonstrated any concern for residual thrombosis or embolic phenomena. Of the 
two listed above that did, the first article reported blood clots seen by 
transesophageal echo on the devices in two adult patients at two and six weeks, 
respectively, after intervention.94 They were treated with warfarin and had no specific 
sequelae. The second reference lists 9 out of 139, or 6%, of their adult patients noted 
to have thrombus formation seen by TEE in the first two weeks post-procedure.95 
One of these patients, who had a factor XII deficiency, had a cerebral embolism 
within two days of the procedure; however, the thrombus self-resolved within one 
month. One patient underwent surgical removal for an asymptomatic thrombus, and 
the remainder had theirs resolve within three to five weeks. Of interest, none of these 
patients had residual shunting noted, none of the thrombi were seen by transthoracic 
echo, and none of the pediatric patients had thrombotic complications. 
 Radiofrequency ablation 
Radiofrequency ablation involves the creation of an endocardial burn to cause tissue 
disruption within an abnormal electrical cardiac focus, such as accessory pathways, 
automatic foci, etc. This is achieved by applying alternating current through a 
catheter in contact with the endocardium. The current causes the burn by creation of 
resistive heating within local tissues.105 There is heat transfer to the surrounding 
blood, which is increased in scenarios of poor myocardial-catheter tip contact. To a 
lesser extent, there is also heat transfer to deeper tissue and epicardial coronary 
arteries that is dependent on duration of exposure. Therefore, thrombus formation 
can occur in the blood pool, at the direct site of ablation, and in epicardial coronary 
arteries adjacent to the ablation site. Pathologic studies have, in fact, demonstrated 
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fibrinous collections and even thrombi at the ablation site.105 (Figure 4) Reported 
thrombotic complications, though, have been few and on the order of 0.6 to 2.8%, 
depending on the location of the lesion and the type of tachycardia.106,107 These 
include microthrombus formation with embolism and coronary artery thrombosis due 
to local energy application from an intracardiac or intravascular catheter. Systemic 
thrombotic and embolic phenomena secondary to instrumentation or prolonged 
immobilization associated with the ablation procedure, leading to venous occlusion, 
cerebral or pulmonary embolus, and deep venous thrombosis, are recognized 
thrombotic complications as well.106–109 Mechanisms to control and direct the amount 
of thermal injury have included temperature monitoring of the catheter tip, manual or 
automatic impedance monitoring mechanisms, and newer saline-cooled catheters.110 
Anticoagulation during radiofrequency ablation has been typically similar to that of 
left-sided pediatric cardiac catheterization, with heparinization at 100 u/kg bolus 
given initially followed by maintenance with either continuous infusion of 15-20 
u/kg/h, or repeated bolus of 20-50 u/kg/h,111 or as dictated by ACT.112 Some groups 
will maintain the ACT greater than 300.112 This is continued until the catheters are 
removed. There have been varying protocols for maintenance of prophylactic 
anticoagulation post-ablation. Different institutions will give aspirin 3-5 mg/kg/day for 
two to six weeks post-ablation, although one facility treated for three months,112 and 
another did not treat at all.113 Nevertheless, the occurrence of thromboembolic events 
appears to be independent of the anticoagulation protocol.106 No double-blind, 
randomized, placebo-controlled studies exist evaluating the efficacy or even the need 
for anticoagulation agents after ablation. 
 
Figure 4 Thrombus formation in the left main coronary artery after inadvertent direct 
application of radiofrequency energy to the left coronary artery ostium of a teenager 
during radiofrequency ablation of a left-sided pathway. Image courtesy of Amy 
Martin, M.D., Office of the Medical Examiner, Denver, CO. 
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 Post-catheterization vessel occlusion 
Cardiac catheterization has evolved from a mostly diagnostic procedure to a more 
interventional use. Its utility has increased for patients who require some sort of 
intervention, but may be able to rely on the new generation of non-surgical 
techniques that can either increase or decrease flow, as appropriate. Since the 
femoral artery has been the major entry vessel of choice, one of the significant 
complications is femoral arterial occlusion. Strategies that have reduced the 
incidence of arterial occlusion include the use of percutaneous access over 
arteriotomy,114 indwelling arterial sheaths to keep vessels patent for catheter 
exchanges,115 smaller balloon and catheter profiles to create less vessel damage,116 
and double-balloon valvuloplasty techniques to reduce exposure of the arteries to 
larger catheters.117 Typically, the background incidence of arterial complications is 
felt to be higher in patients 5 years of age, or younger.118 The mechanism of 
occlusion is complex, and felt to be due to combinations of spasm, thrombus 
formation at the catheter or sheath, or intimal disruption and flap formation with 
varying degrees of complicating polycythemia, small size, and low cardiac output.119–
122 These lead to either transient or complete loss of pulse. Routine systemic 
heparinization during the catheterization has significantly reduced the incidence of 
this problem.123 Typical anticoagulation at the start of arterial cannulation consists of 
IV heparin 50-100 units/kg given as a bolus. Subsequently, heparin can be given 
empirically at another 50 units/kg IV bolus for each subsequent hour. Alternatively, 
ACT levels can be monitored, with maintenance at >200 seconds as adequate 
anticoagulation.124 A study looking to further reduce this occurrence using intra-
arterial papaverine was too small to demonstrate significant effects.125 However, it 
was able to demonstrate that ultrasound diagnosis of femoral arterial occlusion, using 
specifically the pulsatility index, could be made with good sensitivity and specificity if 
the pulsatility index was less than 3.34. 
Once loss of pulse is determined, by clinical findings such as decreased distal 
pulses, cool extremity, edema, and color change and/or by abnormal ultrasound 
findings, using an algorithmic intervention scheme can be quite helpful.126 Repeat 
systemic heparinization is usually performed with 100 units/kg bolus IV followed by 
continuous infusion of 20 units/kg/hour IV for four hours. If pulse has not returned 
despite improved perfusion, check an aPTT bolus and adjust the heparin infusion to 
attain an aPTT 2.5 times control values. If there is still no improvement, thrombolytic 
therapy with either streptokinase, at 1000 units/kg bolus and 1000 units/kg/hour for 6 
hours, or rTPA, at 0.7 mg/kg bolus and 0.2 mg/kg/hour for 6 hours OR 0.1-0.5 
mg/kg/infusion without initial bolus but with incremental 0.1 mg/kg/hour increases, 
can replace the heparin. Baseline prothrombin and thrombin times, hemoglobin, 
fibrinogen, repeat aPTT, and type and cross for one unit of packed red blood cells 
should be obtained. End points include return of pulse, entry point site bleeding, 
internal bleeding, or no response or worsening of the limb's status. Continuing to 
surgical embolectomy or intimal flap repair is dependent upon whether viability of the 
leg is still in concern or if adequate thrombolysis fails despite fibrinogen levels <1.9. If 
thrombolysis successfully returns pulse and perfusion, continued observation for 24 
hours after discontinuing therapy is important to ensure that other hemorrhage does 
not occur and that arterial patency is maintained. 
 Blalock-Taussig shunts 
The original Blalock-Taussig shunt, a systemic to pulmonary shunt created by 
anastomosing the subclavian artery end to side to the ipsilateral pulmonary artery, 
has largely been replaced by the modified Blalock-Taussig shunt, a 
polytetrafluoroethylene tube graft that is interposed end-to-side between the 
subclavian and pulmonary arteries, or by a modified central shunt, in which a tube 
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graft is anastomosed between the ascending aorta and pulmonary artery. However, 
because of their high flow, short distance, and small diameter, these shunts can 
thrombose and occlude. Typically, patients who receive these shunts are given 
heparin intraoperatively to prevent occlusion, although one recent study suggests 
that it may be a significant risk factor in the development of perioperative seroma.127 
Some patients are then treated with low-dose aspirin (1-10 mg/kg/day), but there has 
also been a study concluding that after a single intraoperative low-dose of heparin 
(20 u/kg), no further anticoagulation is required.128 In that study of twenty-five 5 mm 
shunts, there were no acute shunt failures noted, and only one patient required shunt 
angioplasty six months after the shunt was inserted. An earlier study reports “shunt 
failure” in 10 of 55 non-anticoagulated patients (only one was 4 mm; the remainder 5 
or 6 mm).129 Shunt occlusion was not demonstrated. Five patients experienced 
proximal suture line stenosis. Furthermore, their definition of shunt failure also 
included isolated increased serum hemoglobin. Another study from 1985 followed 19 
patients who received shunts of four, five, and six millimeters in diameter.130 Two 
patients lost partial or complete patency of their 4 mm shunts; neither of these 
patients had been treated with anticoagulation therapy of any kind. Two other 
patients, who also received 4 mm shunts, but received aspirin 10 mg/kg/d, had 
patent shunts but occlusion of the subclavian artery distal to the shunt. The other 
three patients who received 4 mm shunts received ASA as well, and had no 
complications. Patients with 5 and 6 mm shunts had no complications, but were not 
given any specific therapy. In a study of patients less than three months of age at the 
time of shunt placement, 20 received 5 mm and 43 received 4 mm shunts.131 They 
were given heparin 1 mg/kg/day in the first three to five postoperative days, then 
given undefined aspirin therapy for an undefined “long” period of time. A total of 27 
shunt failures were noted, with 20 of these in the 4 mm grafts, and five of these 
failures occurring within the first month. Univariate and multivariate analysis 
demonstrated that the use of a 4 mm shunt conferred a greater risk of shunt failure 
than the use of a 5 mm shunt. Nevertheless, approximately 85% of the shunts were 
adequately functioning one year after implantation. Over the long term, 18% of the 4 
mm and 25% of the 5 mm shunts demonstrated distortion of the pulmonary artery, 
and 10 of the 20 shunts failed secondary to distortion at the proximal anastomoses. 
Smaller shunts associated with PA distortion did not incur failure of shunt patency 
more than the larger shunts. 
At the present time, the ACCP consensus study recommendation has been to initially 
give perioperative therapeutic heparin followed by indefinite treatment with aspirin 3 
to 5 mg/kg/day.1 Certainly, one factor that will play into the need for and duration of 
shunt survival is the increasingly younger age at which patients receive their 
definitive repair. Many patients were palliated with shunts and allowed to grow until 
definitive repair occurred two or more years later. With the advent of better 
techniques and knowledge of cardiopulmonary support, the time from palliation to 
complete repair has diminished, thus requiring less overall need for an increased 
duration of patency of a shunt. As well, this trend toward earlier intervention has led 
to a bypassing of the use of shunts, opting for early complete repair as initial 
intervention. To be sure, there will still be complex pulmonary atresia patients and the 
like who require longer periods of shunt survival to achieve adequate pulmonary 
artery growth. 
 Myocardial ischemia and infarction 
Myocardial ischemia and myocardial infarction (MI/MI) are very infrequent events in 
children. Hence, there is really no literature that has thoroughly evaluated various 
anticoagulation treatment regimens in children. Furthermore, the etiologies of MI/MI 
are typically much more diverse than in adults, who most likely have coronary artery 
atherosclerosis as their primary etiology. Pediatric etiologies for MI/MI include: 
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Kawasaki disease, anomalous coronary artery origin, course, or bridging. Congenital 
heart diseases, cardiomyopathy, genetic disorders, substance abuse, trauma, 
systemic disease resulting in poor perfusion, iatrogenic intervention (surgical or 
medical), and idiopathic or premature coronary artery disease.132,133 However, since 
the majority of these disease states require medical (including inotropic), surgical, or 
mechanical support, there has not been a drive for studying of anticoagulation in this 
patient population. Thus, as in many other adult disease-model analogues, the model 
for care for pediatric patients with MI/MI mirrors that of the adult. Since the use of 
anticoagulation in adults with MI/MI is based on a consistent and well-studied model 
in which long-standing atherosclerosis acutely impairs coronary flow, and some 
pediatric diseases may have a similar picture resulting in coronary artery obstruction, 
we will briefly summarize adult anticoagulation management of MI/MI. 
The principles of anticoagulation therapy in adult MI/MI are to prevent further 
thromboembolic formation and extension in coronary arteries while not increasing 
risk to the patient for intracranial bleeding. Active thrombolytic therapy will not be 
addressed, however, since the need for this in pediatric patients is much more 
limited. These are used as direct agents in destroying thrombus on ruptured 
atherosclerotic plaques that have obstructed the coronaries. Yet, the use of platelet-
active drugs, antithrombotics, and anticoagulants may be reasonable adjunctive 
therapy in the management of pediatric MI/MI. These are agents that act to prevent 
further creation and propagation of thrombus. However, there has been no study of 
the use of these agents for this purpose in children. Extrapolation of the use of these 
agents may be made, based on what is known about effective dosing in children. 
One of the most useful, and inexpensive, agents studied is aspirin. The study that 
best proved its effectiveness was the ISIS-2 study, in which 162.5 mg of aspirin was 
crushed or chewed and taken orally for one month.134 It decreased mortality, risk of 
reinfarction, and risk of stroke. The first dose was given soon after diagnosis to 
achieve rapid platelet inhibition, which occurs within one hour. The effective dose is 
160 to 325 mg in adults, as lower doses delay the onset of platelet inhibition.135 
Subsequent adult doses for long-term platelet inhibition can be as low as 75-160 
mg/day.136 Continued therapy has been shown to be protective for up to 1-2 years. 
Contraindications to aspirin therapy include aspirin allergy, active bleeding (including 
GI or GU sources), and hemophilia. 
Patients who cannot take aspirin may be given ticlopidine or clopidogrel.136 
Ticlopidine takes 24 to 48 hours for initial effect, and may not achieve its maximal 
effect until two weeks. As well, its side effect profile includes GI disturbance and 
neutropenia. The adult dose that has been used is a loading dose of 500 mg followed 
by 250 mg twice daily, with required monitoring of white cell and platelet counts. As 
mentioned previously, ticlopidine has been used in the setting of Kawasaki's disease 
with coronary artery involvement.68 Recent data suggest that clopidogrel is as 
effective as ticlopidine, is better tolerated due to its better safety profile, and actually 
acts faster as a platelet-inhibiting agent. This can be given as a loading dose of 300 
to 600 mg, and then followed with daily therapy of 75 mg/day. There are no data 
regarding clopidogrel use in children. Medications such as dipyridamole, 
sulfinpyrazone, and prostacyclin and its analogues have not been shown to be 
effective for patients with unstable angina or non-ST-segment-elevated MI, and are 
thus not used.136 
Anticoagulants, such as unfractionated heparin and low molecular weight heparin 
(LMWH), are adjunctive therapies that are typically used in combination with active 
thrombolytic therapy. However, older data demonstrate that heparin monotherapy 
has reduced mortality and risk of reinfarction.137 Yet, since the ISIS-2 study 
demonstrated that aspirin is effective with heparin as well,134 most studies now will 
not assess heparin as a single therapeutic agent.135 Looking at it from the reverse, 
after the evaluation of the GUSTO-1,138 GISSI-2,139 and ISIS-3140 trials, the addition 
of heparin to aspirin does not appear to confer any advantage over aspirin alone, and 
JR Boris and MA Harris. The use of anticoagulation in pediatric cardiac disease. Images Paediatr 
Cardiol. 2003 Jul-Sep; 5(3): 1–35. 
 17 
seems to add an increased risk of significant bleeding.135 Recent reviews on 
managing adult MIs disapprove of the use of heparin completely,135 or generally lean 
away from its use.141 Interestingly, an update of the American College of 
Cardiology/American Heart Association Guidelines for the Management of Acute 
Myocardial Infarction further reviewed the use of LMWH, and referenced several 
studies showing that various formulations of LMWH were superior to unfractionated 
heparin plus aspirin or aspirin alone.142 Furthermore, even suggested consideration 
of these as individual, and not interchangeable, drugs; nadroparin and enoxaparin 
were demonstrated to have a higher anti-Xa:anti-IIa ratio in vitro than dalteparin, and 
may be more effective clinically. Overall, enoxaparin was shown to be better than 
unfractionated heparin at not only reducing death and serious cardiac ischemia, but 
also not increasing the rate of major hemorrhage in the short term (under 45 days). 
There is less overall heparin-induced thrombocytopenia,143 it can be given 
subcutaneously (obviating the need for continued intravenous access), and requires 
no specific monitoring. When used in children, dosing ranges have been described 
as either therapeutic or prophylactic, with differing doses based on whether the 
patient is less than two months old or older, and whether the scenario is low or high-
risk.144 Therapeutic doses for patients under two months of age are 1.5 mg/kg every 
12 hours; prophylaxis doses are 0.75 mg/kg every 12 hours if low-risk, 1.5 mg/kg if 
high-risk. For patients between two months and 18 years of age, therapeutic dosing 
is 1.0 mg/kg every 12 hours and prophylactic dosing is 0.5 mg/kg every 12 hours for 
low-risk and 1.0 mg/kg for high-risk. High and low-risk definitions were derived from 
the clinical scenarios in the study for which LMWH was used. Examples of high-risk 
scenarios included cardiomyopathy, prosthetic mitral valve, cardiovascular shunts, 
systemic lupus erythematosus, and central venous line-related thrombosis with a 
previous thrombotic event. Low-risk scenarios included central venous line-related 
thrombosis with no thrombotic history, and trauma after surgery. MI was not one of 
the clinical scenarios. 
The GP IIb/IIIa inhibitors, abciximab, eptifibatide, and tirofiban, have been initially 
evaluated in the settings of acute coronary syndromes, unstable angina, non-Q wave 
MI, and percutaneous coronary interventions. However, they have not been 
evaluated in comparison to each other. When compared as a group to placebo and 
as an adjunct to aspirin and unfractionated heparin therapy, they appear to decrease 
the occurrence of MI plus death, or MI plus need for coronary artery bypass or plus 
death.136,142 Dosing guidelines are as listed previously, although as also previously 
mentioned, any pediatric experience with these medications is extremely limited. Yet, 
to reiterate a prior discussion, abciximab may have some efficacy in not only the 
prevention of thrombosis but may confer some improved vascular remodeling.69 
 Kawasaki Disease 
Kawasaki disease, first described in 1967145, is an inflammatory syndrome of the 
medium-sized arteries that leads to acute coronary artery damage with myocardial 
infarction, and with the potential for chronic coronary artery aneurysm or stenosis. It 
has undergone a series of modifications to its therapeutic scheme that culminated in 
the American Heart Association report on diagnosis and therapy.146 Besides anti-
inflammatory treatment, anticoagulation to prevent coronary thrombosis has been a 
cardinal feature of the therapies. Management of acute Kawasaki's disease includes 
administration of IV immunoglobulin at a dose of 2 g/kg over 12 hours plus oral 
aspirin 80 to 100 mg/kg/day divided QID for up to 14 days from the onset of the 
illness followed by platelet inhibiting aspirin doses of 3-5 mg/kg/day for 6 to 8 weeks 
after the acute phase. Initial therapy has been shown to be most efficacious prior to 
day 10 of the illness. This has been demonstrated to decrease the incidence of 
coronary artery complications from 20-25% to 5%.147 A repeat dose of IVIG may be 
used for initial treatment failure.148 Previously, use of corticosteroids was believed to 
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lead to an increased incidence of coronary artery thrombosis.149 Recent studies, 
though, suggest that it may be more efficacious150, such as in those patients who are 
refractory to an initial dose of IVIG151–153 or have recurrence of symptoms. IV 
methylprednisolone at a dose of 30 mg/kg/day given over 1-3 days has been 
successfully used in these patients.151 Alternatively, oral methylprednisolone, 2 
mg/kg/day for two weeks followed by a tapered dosing regimen over six weeks, 
seems to have been effective in the face of persistent fever, progressive cardiac 
disease, or worsening vasculitis.154 Newer therapies, such as antiplatelet agents like 
ticlopidine61 and abciximab68,69 (mentioned previously in this article), have also been 
used with increasing success in the acute setting, potentially including enhanced 
resolution of giant coronary aneurysms. Pentoxifylline, as previously mentioned, has 
been used in combination with IVIG and ASA with dubious results in aneurysm 
prevention13,155. Long-term prophylactic anticoagulation of patients who have 
coronary artery complications includes low-dose aspirin (3-5 mg/kg/day) and warfarin 
(to maintain an INR of 2.0 to 3.0), depending on the presence and size of the 
coronary arteries aneurysms and the presence of coronary artery stenoses.156 
Dipyridamole, at 2-3 mg/kg/dose BID to TID, may be used temporarily (typically 
approximately two weeks) for patients on chronic aspirin therapy who have been 
exposed to either varicella or influenza. This especially is done in patients at greater 
risk for myocardial infarction.157 In patients who have had myocardial ischemia or 
infarction, or other thrombotic complications, thrombolysis has been successfully 
performed, variably using exercise plus systemic heparin158, or systemic or 
intracoronary streptokinase159,160, urokinase161, or tissue plasminogen activator.162 
There are no randomized, double-blind, placebo-controlled trials that assess the 
various anticoagulation therapies for Kawasaki's disease. The American Heart 
Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease 
periodically reviews these agents and reports of their use through the literature, and 
modifies their treatment recommendations146,156 ; an update after their recent 
conference is pending. 
 
Cardiomyopathy 
 Dilated cardiomyopathy 
Unlike in adults, dilated cardiomyopathy in children tends to be idiopathic rather than 
ischemic in etiology. However, the cardiovascular and pathologic features remain 
similar, including poor cardiac output and congestive heart failure, varying degrees of 
mitral valve regurgitation, and risk for left ventricular thrombus with 
thromboembolism.163–165 The incidence of thrombus formation is variably reported 
ranging between 13-23%163,165,166 and the incidence of systemic embolic events 
ranges from 8-14%.163,165–167 (Figure 5) Pulmonary embolism has also been reported 
in patients with dilated cardiomyopathy.168 Since the incidence of pediatric dilated 
cardiomyopathy is low, the studies that describe the findings in this age group are all 
retrospective, and have not addressed randomization of anticoagulation regimens. 
Most reports in pediatric patients discuss the use of either aspirin or warfarin,163–165 
but often do not address dosing regimens. Many of these are initiated post-hoc when 
thrombus or an embolic event has already been diagnosed. One case report series 
from Germany did give their dosing regimen for the treatment of LV thrombus as 
aspirin 25 mg/kg plus dipyridamole 6 mg/kg; this led to resolution of thrombus (by 
echocardiography) in five to seven weeks in their three patients.169 These patients 
were found to have thrombus either after diagnostic echocardiography for congestive 
heart failure, or after cerebrovascular accident. The incidence of thrombus formation 
in their series of patients was 33%. Of note, two of their patients had recurrence of 
thrombus formation diagnosed by echocardiography, despite continued aspirin and 
dipyridamole therapy. Unfortunately, intracardiac thrombus in the setting of dilated 
JR Boris and MA Harris. The use of anticoagulation in pediatric cardiac disease. Images Paediatr 
Cardiol. 2003 Jul-Sep; 5(3): 1–35. 
 19 
cardiomyopathy, as in Fontan patients, is not reliably diagnosed by transthoracic 
echocardiography and is sometimes only found on autopsy.167,168 
Adult studies of dilated cardiomyopathy have not looked at randomized regimens of 
platelet-inhibition versus anticoagulation. A retrospective look at data from the 
Studies of Left Ventricular Dysfunction (SOLVD) trial demonstrated that warfarin use 
decreased overall mortality (although again there was no dosing or monitoring 
information available).170 It did demonstrate that they had less aspirin use in the 
patients who were treated with warfarin as compared to those who were not treated 
with warfarin, to suggest that aspirin may not have been protective against death 
overall. Of note, though, only 50% of the patients who had not used warfarin had 
been on aspirin, and over 75% of both groups were smokers, which may have 
confounded the findings. In addition, warfarin seemed to confer protection from direct 
cardiovascular causes of death (e.g. sudden death, death associated with heart 
failure, and MI) in contrast to death from extracardiac, embolic events (in which there 
was no actual difference noted between those treated with or without warfarin). A 
review performed in the same year countered these findings, however, by suggesting 
that aspirin monotherapy was effective in preventing thromboembolism, stroke, and 
sudden death in adults.171 This study also included data from the SOLVD study, as 
well as three other major studies and four small studies; all were retrospective and 
non-randomized in nature. 
The mechanism of thrombus formation in the face of dilated cardiomyopathy has 
been attributed to lower Doppler flow velocities across the mitral valve, to the apex, 
and outflow from the left ventricle.172 In this same study from Maze, et al, mitral 
regurgitation, with its attendant increased inflow velocities, was suggested as being 
somewhat protective and lead to decreased findings of LV thrombus in adult patients. 
This concept has been mentioned in other studies, as well.173,174 However, a study 
from Hong Kong that looked at platelet function and its relationship with mitral 
regurgitation concluded that MR is a risk factor for thrombus formation, and also 
provided a possible mechanism.175 They demonstrated that patients with mitral 
regurgitation had higher levels of platelet factor 4 and beta-thromboglobulin, both 
markers of platelet activation, than patients without valvular leak. Yet another way of 
approaching the problem was looked at in Vienna, in which the investigators studied 
flow and clotting factors along with the formation of spontaneous echocardiographic 
contrast as a precursor to potential thrombosis.176 Spontaneous echo contrast was 
seen more frequently in patients presenting with a thromboembolism, and left atrial 
appendage flow velocities were found to be lower in patients with atrial thrombus. 
But, there were patients who had thrombi, and yet had normal velocities. As well, 
although plasma fibrinogen and plasma viscosity were statistically significantly higher 
in patients with spontaneous echocardiographic contrast than those without, these 
data were only slightly different while an entire battery of rheologic variables were 
otherwise determined to be no different between groups. Therefore, there is no 
consensus as to the mechanism of thrombus formation. With the contradictory 
findings in these studies, and the continued demonstration of thrombus formation in 
patients who have dilated cardiomyopathy regardless of mitral valve function, mitral 
regurgitation may not be an adequate predictor of the formation of thrombus. Thus 
future randomized prospective studies in both adults and children will need to be 
designed, with attention to the ventricular flow characteristics as part of the trial. 
An interesting adjunctive therapeutic use was suggested by Sliwa, et al., in which 
pentoxifylline was used, in combination with digoxin, ACE inhibition, and carvedilol or 
diuretics, in a series of small prospective, randomized, placebo-controlled, double-
blind studies of adult patients177–179. By taking advantage of pentoxifylline's ability to 
reduce TNF-alpha and Fas/Apo-1, they were able to demonstrate significant 
increases in LV ejection fraction in the treatment group over placebo after one month 
as well as falls in TNF-alpha and Fas/Apo-1. In these series, pentoxifylline was not 
used specifically as a coagulation-modulator. Instead, the investigators took 
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advantage of one of its side effects to achieve their goals. Since these cytokines are 
elevated in pediatric cardiomyopathies, larger studies could lead to a potentially 
exciting therapy for this poorly understood medication. 
 Left ventricular noncompaction 
Isolated ventricular noncompaction is considered an unclassified cardiomyopathy by 
the World Health Organization.180 It has been associated with both pulmonary 
embolism181 as well as systemic embolism, including cerebrovascular accidents, 
transient ischemic attacks, mesenteric infarctions,182 and saddle emboli to the 
abdominal aortic bifurcation.183 Intramural thrombus has been demonstrated by 
echocardiography,182,183 MRI, endomyocardial biopsy,181 and at necropsy.183 Oral 
anticoagulation has been recommended for these patients,182,183 although no data 
exist regarding the long-term outcome of these patients after anticoagulation. 
Typically, the prognosis for these patients is guarded, as they tend to have 
progressive ventricular dysfunction and dysrhythmias that cause morbidity and 
mortality independent of embolic phenomena. There have been no prospective 
studies in adults or children assessing the efficacy of any anticoagulation regimen. 
 Mechanical ventricular support devices 
Ventricular assist devices have been in increasing use in pediatric patients. As with 
much of the technology, the initial tests and devices were performed on adult 
patients. With the advent of improved miniaturization, devices were developed for 
use in children, although the use and study of these in pediatric patients significantly 
lagged behind adult assist device development since the incidence of children 
requiring these devices is greatly less than the adult population. As well, using simply 
scaled-down versions of adult-sized equipment has demonstrated increased 
thrombogenicity of the smaller devices, despite using geometrically similar models.184 
Furthermore, extracorporeal membrane oxygenation (ECMO) has been much more 
widely used and accepted in children. Improvements in flow studies and 
understanding of fluid dynamics, however, have led to wider use and advances in 
their design. Their uses have included a bridge to transplant support function, rescue 
post-operatively, and support during acute myocarditis. We will not discuss the use of 
ECMO, as it is beyond the scope of this review. For more information regarding the 
history and early development of pediatric use of these devices, please refer to the 
review by Pennington and Swartz from 1993.185 
Left ventricular and biventricular assist devices have been used as early as 1963186, 
but the majority of the clinical experience has centered on the Biomedicus centrifugal 
pump system, and the pneumatic pumps, the "Berlin Heart" and the Medos-HIA VAD. 
Use of the Biomedicus centrifugal pump circuit requires heparin infusion at 10-20 
units/kg/h to maintain the activated clotting times between 170 and 200 seconds, or 
the activated partial thromboplastin time at 1.5 times control value.187 Reported 
complications include various neurologic sequelae.188 The “Berlin Heart,” a 
pneumatic pump developed in Germany, has been used since 1992.189 It uses 
heparin-coated cannulae (although initial uses of the system did not included 
heparin-coated catheters), and requires systemic heparinization to keep activated 
clotting times between 140 and 160 seconds. Thrombi were detected in the systems 
where non-heparin-coated catheters were used; in subsequent patients who had 
heparin-coated cannulae, there were no further reports of thrombi. In all sets of 
patients, however, there was evidence of neurologic sequelae and bleeding 
complications, including hemorrhagic pericardial effusions.190 The Medos-HIA VAD, 
another pediatric VAD developed in Germany, was first described in 1988.191–193 It is 
also pneumatically driven, but uses systems that are not heparin-bonded, so that 
protamine can be administered to discontinue bypass.194 It is heparinized to keep the 
activated clotting time between 180 and 200 seconds or a partial thromboplastin time 
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greater than 50 seconds, with longer runs requiring the addition of aspirin 5 
mg/kg/day after removal of chest tubes. Transient minor ischemic attacks and visible 
thrombi (during a period of inconsistent activated clotting time maintenance), and 
retroperitoneal bleeding (in the same patient, after increased anticoagulation) have 
been reported,192 as well as multi-organ failure.193 The Hemopump, an axial 
continuous flow, turbine-style pump, had been used somewhat in children in the U.S., 
although it was used more extensively in Europe195 and Canada.196 It used no 
anticoagulation, and seemed to be well tolerated overall, by reports. However, the 
device is no longer available in its present form; a German firm, Impella AG, is 
reportedly developing a similar intravascular system. 
Intra-aortic balloon pumps have been available in pediatric sizes since the early-
1980's.197 The Datascope balloon pump has been used in the setting of heparin 
infusion to keep the partial thromboplastin time 1.5 to 2 times the normal value.198 
Complications include cerebrovascular accidents, renal and mesenteric ischemia,198 
and saphenous venous thrombophlebitis.199 They are typically used in larger children, 
as they are placed transvenously in the femoral vessels and can be quite occlusive to 
flow, risking long-term patency of the femoral vessels. A recent report from the adult 
balloon pump benchmark registry showed that smaller BSA (<1.65 m2) was one of 
the independent risk factors for serious complications, such as limb ischemia and 
bleeding, confirming pediatric findings.200 Furthermore, higher pediatric vascular 
compliance tends to limit their effectiveness. Despite this, it has been used 
successfully in children weighing as low as 1.9 kg,201 with subsequent reports 
successfully using them in patients as low as 3.1 kg202 and 4.3 kg.203 The review from 
Utah suggested continuous infusion of heparin at a rate of 10 to 15 u/kg/hour, 
monitoring aPTT.202 In the latter report, the patients were systemically heparinized to 
maintain an activated clotting time of 180 to 200 seconds without complications.203 A 
previous report from Utah, describing 18 patients with a majority of the children under 
10 kg, also recommended maintaining aPTT at twice normal.204 
 
Conclusion 
The concept of pediatric anticoagulation has been one that has been simultaneously 
widely embraced and little understood. Despite increasing use, there is a slowly 
growing, mostly retrospective or case-reported, experience of how these agents 
affect children combined with a widening gap between adult and pediatric experience 
with the emerging therapies. As has been shown here, there remains a dearth of 
prospective, randomized pediatric data, despite great strides by a number of 
research centers to deepen the known information about these drugs in children. It 
will most likely remain that anecdotal uses will continue to lead the foray into effective 
use of anticoagulation, eventually followed by larger single or multi-center studies 
that better define the successes and failures of these agents, their doses, and their 
pharmacokinetics, plus give accurate side-by-side comparisons of these agents. As 
well, the continued following of the lead of adult practitioners will give, at least, initial 
insights into which therapies may be adapted for pediatric use. It is the hope that 
defining some of the adult regimens here will stimulate further thought and utilization 
of newer agents in children, where appropriate. In the United States, efforts by the 
Food and Drug Administration since 1998205 to obtain more pediatric data on a host 
of newer medications, by exchanging six extra months of patent protection and 
“pediatric exclusivity” for the development of this information, has already borne fruit 
in multiple medications.206 Further similar efforts may be of benefit down the line for 
these medications, as well, both from a retrospective standpoint for already released 
medications as well as for new therapies. In the end, it will be up to both the pediatric 
research community and to the drug companies, which may even lead to joint efforts, 
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to make develop unbiased, accurate, and useful data for appropriate deployment of 
the varied anticoagulation entities available for use. 
One sad note: one of the driving forces behind the organization of strong pediatric 
coagulation research and the maintenance of good pediatric anticoagulation 
practices, Maureen Andrew, M.D., who died during the production of this manuscript, 
at the age of 49. Her ubiquitous and pioneering presence throughout the world of 
pediatric hemostasis, thrombosis, and anticoagulation will be truly missed. 
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